You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for Patent: 6,656,935


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 6,656,935 protect, and when does it expire?

Patent 6,656,935 protects STENDRA and is included in one NDA.

This patent has forty-one patent family members in twenty-five countries.

Summary for Patent: 6,656,935
Title: Aromatic nitrogen-containing 6-membered cyclic compounds
Abstract:An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): ##STR1## wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R.sup.1 is a substituted or unsubstituted lower alkyl group, --NH--Q--R.sup.3 (R.sup.3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or --NH--R.sup.4 (R.sup.4 is a substituted or unsubstituted cycloalkyl group); R.sup.2 is a substituted or unsubstituted aryl group; one of Y and Z is .dbd.CH--, and the other is .dbd.N--, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.
Inventor(s): Yamada; Koichiro (Saitama-ken, JP), Matsuki; Kenji (Saitama-ken, JP), Omori; Kenji (Saitama, JP), Kikkawa; Kohei (Kawaguchi, JP)
Assignee: Tanabe Seiyaku Co., Ltd. (Osaka, JP)
Application Number:09/925,892
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,656,935
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,656,935

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y TREATMENT OF ERECTILE DYSFUNCTION ⤷  Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 AB RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y TREATMENT OF ERECTILE DYSFUNCTION ⤷  Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y TREATMENT OF ERECTILE DYSFUNCTION ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,656,935

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11-261852Sep 16, 1999
Japan2000-130371Apr 28, 2000

International Family Members for US Patent 6,656,935

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1219609 ⤷  Sign Up 92249 Luxembourg ⤷  Sign Up
European Patent Office 1219609 ⤷  Sign Up CA 2013 00040 Denmark ⤷  Sign Up
European Patent Office 1219609 ⤷  Sign Up C300618 Netherlands ⤷  Sign Up
European Patent Office 1219609 ⤷  Sign Up 13C0050 France ⤷  Sign Up
European Patent Office 1219609 ⤷  Sign Up 1390047-7 Sweden ⤷  Sign Up
European Patent Office 1219609 ⤷  Sign Up 2013/041 Ireland ⤷  Sign Up
European Patent Office 1219609 ⤷  Sign Up 122013000096 Germany ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.